Related Experiment Videos
The prophylactic treatment of retrolental fibroplasia
Insights
Photocoagulation and cryocoagulation therapy for retinopathy of prematurity (ROP) showed no significant long-term benefits or harm in a trial. Further research is needed before treating stage 3 ROP.
Area of Science:
- Ophthalmology
- Neonatal Medicine
- Pediatric Surgery
Background:
- Retinopathy of prematurity (ROP) is a significant cause of visual impairment in premature infants.
- Stage 3 ROP poses a risk for severe visual complications, including retinal detachment.
- Current treatment options for ROP aim to prevent vision loss.
Purpose of the Study:
- To evaluate the early outcomes and potential benefits of photocoagulation and/or cryocoagulation therapy for stage 3 retinopathy of prematurity.
- To assess the impact of this therapy on macular dragging and refractive error in treated infants.
- To provide preliminary observations to guide future treatment decisions for ROP.
Main Methods:
- A cohort of 10 premature infants with stage 3 ROP received photocoagulation and/or cryocoagulation in one eye.
- Infants were followed for 1-6 years post-treatment.
- Observations included changes in vascularity, macular dragging, refractive error, and incidence of retinal detachment.
Main Results:
- Early observations suggest the therapy is neither significantly beneficial nor harmful in the long term for stage 3 ROP.
- No apparent alteration in refractive error was observed.
- Marked amelioration of vascular dilatation and tortuosity at the posterior pole was noted shortly after treatment.
- Macular dragging was not influenced by the treatment.
Conclusions:
- The long-term efficacy of photocoagulation/cryocoagulation for stage 3 ROP remains uncertain.
- Treatment for stage 3 ROP should be deferred until more definitive beneficial results are established.
- Stage 4 retinopathy (retinal detachment) may be amenable to buckling procedures.
Abstract:
10 premature infants with stage 3 retinopathy of prematurity have had photocoagulation and/or cryocoagulation therapy to one eye and have been followed for a period of 1-6 years. Although the long-term results of this therapy are not known, particularly in the prevention of retinal detachment, early observations suggest that treatment is neither harmful nor particularly beneficial. Macular dragging does not seem to be influenced by treatment. The refractive error, as one would expect, does not appear to be altered by this form of therapy. Marked amelioration of the vascular dilatation and tortuosity at the posterior pole is apparent shortly after treatment. It is stressed that this is a trial project and until more definite beneficial results are obtained, treatment of stage 3 retinopathy should be deferred. Retinal detachments (stage 4) may be quite amenable to a buckling procedure.